Access Statistics for Mary K. Olson

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Pharmaceutical Expenditure and Regulatory Policy in the NHS 0 0 0 0 0 0 0 332
Total Working Papers 0 0 0 0 0 0 0 332


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Agency Rulemaking, Political Influences, Regulation, and Industry Compliance 0 0 0 0 0 5 6 366
Are novel drugs more risky for patients than less novel drugs? 0 0 0 29 1 6 14 126
Eliminating the U.S. drug lag: Implications for drug safety 0 0 0 13 1 8 11 119
Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity 0 1 1 3 0 6 12 30
Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity 0 0 0 7 0 4 8 64
Firm Characteristics and the Speed of FDA Approval 0 0 1 42 2 5 7 149
New clinical information and physician prescribing: How do pediatric labeling changes affect prescribing to children? 0 0 0 3 0 6 6 35
Pharmaceutical Policy Change and the Safety of New Drugs 0 0 2 9 0 3 9 75
Political Influence and Regulatory Policy: The 1984 Drug Legislation 0 0 0 0 2 5 7 183
Reassessing the impact of health IT: Hidden costs and consequences of vendor heterogeneity 0 0 2 2 0 7 17 17
Regulatory Agency Discretion among Competing Industries: Inside the FDA 0 0 0 0 0 3 7 194
Regulatory Reform and Bureaucratic Responsiveness to Firms: the Impact of User Fees in the FDA 0 0 0 25 0 8 13 133
Substitution in Regulatory Agencies: FDA Enforcement Alternatives 0 0 0 0 0 3 3 203
The Effects of UK Pharmaceutical Policy on Government Drug Expenditure: Cost Control and Incentives for R&D 0 0 0 12 0 2 3 73
The risk we bear: The effects of review speed and industry user fees on new drug safety 0 0 2 28 0 4 6 143
Total Journal Articles 0 1 8 173 6 75 129 1,910


Statistics updated 2026-03-04